Quantcast

Latest early-stage breast cancer Stories

2010-03-08 15:34:00

REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either...

2010-01-12 07:00:00

REDWOOD CITY, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of a prospective, multi-center, study that showed the Oncotype DX® breast cancer test Recurrence Score® had a significant impact on breast cancer treatment decisions for early-stage breast cancer patients while increasing patient satisfaction and physician confidence in those decisions. The study found that knowledge of a patient's...

2009-12-15 07:00:00

REDWOOD CITY, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. These data were presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held December 9 - 13, 2009,...

2009-12-11 07:00:00

SAN ANTONIO, Dec. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer. The findings, presented as a poster at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (Abstract # 2031), demonstrated...

2009-12-04 07:00:00

REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze Oncotype DX®, the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as...

2009-11-09 15:01:00

BEDFORD, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the fourth quarter and fiscal year ended September 26, 2009. In addition, Hologic today announced the Board of Directors has promoted Robert Cascella to Chief Executive Officer effective...

2009-11-03 09:50:22

Large study finds subset of women that may need additional therapy Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, published Nov. 2 online in the Journal of Clinical Oncology, is the first large study to...

2009-11-02 07:00:00

CHICAGO, Nov. 2 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(®) Electronic Brachytherapy, eBx(TM) System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, will showcase its growing suite of oncology treatment technologies here at the 51st American Society for Radiology and Oncology (ASTRO) Meeting, November 1-5. Available for treatment of early stage breast cancer, endometrial...

2009-10-09 07:00:00

SAN FRANCISCO, Oct. 9 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy...

2009-10-06 07:00:00

REDWOOD CITY, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California. Both studies analyze Oncotype DX®, the company's multi-gene expression test that physicians use to predict the likelihood of...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related